Key Points Wall Street analysts are modestly bullish on the stock. However, the expanding GLP-1 market and Lilly's strong patents suggest it can regain momentum. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has had an impressive run over the past few years. The stock is up 410% over the last five years and 58% over the past 52 weeks. Its performance this year, however, has been a bit more modest, up just 10.1%. So, it's underperforming the broader market, as measured by the S&P 500 (SNPINDEX: ^GSPC) , which gained around 12.5% so far in 2026. I think the deceleration in the stock's climb this year is probably due to its run-up over the past few years, which has made it expensive.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.